Metraipolis › archive › dc_144bb812dfb4
From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis — Europe PMC PMID:42452581
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42452581
- DOI
- 10.3390/jcm15135121
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T13:46:27.837Z
- SHA-256 of the archived text
97d98cfdb2b2a82cd8be5458c7b85f4837767f08d60f10bdd30a9d5c1b9ff727- Stable URL of this page
https://metraipolis.com/documento/dc_144bb812dfb4
How to cite
From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis — Europe PMC PMID:42452581 — Europe PMC (en), https://europepmc.org/article/MED/42452581 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_144bb812dfb4 (Metraipolis archive dc_144bb812dfb4, sha256 97d98cfdb2b2a82cd8be5458c7b85f4837767f08d60f10bdd30a9d5c1b9ff727)
BibTeX
@misc{dc144bb812dfb4,
title = {From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis — Europe PMC PMID:42452581},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42452581},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_144bb812dfb4; sha256 97d98cfdb2b2a82cd8be5458c7b85f4837767f08d60f10bdd30a9d5c1b9ff727},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42452581. Agents can read the archived copy with the MCP tool read_document.